Pangenomic Health Inc. operates as a precision health company in Canada. The company offers Nara App, a telehealth mental health app that provides users with personalized information about non-pharmaceutical alternatives to address mental health concerns; and Mindleap, a telehealth platform, which provides various tools and resources to help individuals understand and improve their inner wellness. It also provides MUJN, a clinical decision support platform that offers health practitioners with access to the consumer's mobile app data and their diagnostic reports. In addition, the company offers vitamin D assessment services and BDNF (brain-derived neurotrophic factor) mental health biomarker health assessment service. The company was formerly known as Zetta Capital Corp. and changed its name to Pangenomic Health Inc. in December 2021. The company was incorporated in 2015 and is based in Vancouver, Canada.…
Pangenomic Health (CNSX: NARA) is listed on the Canadian Securities Exchange, where its shares trade in CAD. It belongs to the Health Information Services industry, part of the Healthcare sector.
The shares were at 0.1800 CAD on 19 November 2026, down 79.1% over 52 weeks. Its 52-week range is 0.1600 CAD to 1.000 CAD: the price is 82.0% below the high and 12.5% above the low.
Its market capitalisation is 4.63M CAD.
Pangenomic Health reports return on equity of 156.8% and an operating margin of 0.0%.
Its debt exceeds its cash by 707.62K CAD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.
No upcoming events tracked.